Nyxoah SA partners with ResMed Germany to increase OSA awareness and therapy penetration in the German market, educating and guiding patients through…

Nyxoah Announces Partnership with ResMed in Germany C reates a continuum of care in the German obstructive sleep apnea market

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has given back its intraday gains and dropped into the red. At the time of writing, the benchmark index is down 0.2% to 7,015.3 points. Four ASX shares that are not letting that hold them back are listed below. Here''s why they are rising: ANZ Group Holdings Ltd (ASX: ANZ) The ANZ share price is up over 1% to $25.50. Investors have been buying the banking giant''s shares today following the release of a bullish broker note out of Morgan Stanley. It has upgraded the bank''s shares to an overweight rating with a $27.00 price target. Lake Resources N.L. (ASX: LKE) The Lake Resources share price is up 6% to 17 cents. This has been driven by the release of an announcement relating to the direct lithium extraction (DLE) technology it plans to use for the Kachi project. Lake advised that Lilac Technologies'' DLE technology has been proven successful through extensive field testing at the flagship project. ResMed Inc (ASX: RMD) The ResMed share price is up a further 4% to $24.00.

Baldwin Brothers LLC MA cut its stake in shares of ResMed Inc. (NYSE:RMD – Free Report) by 7.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,894 shares of the medical equipment provider’s stock after selling 1,010 shares during the quarter. Baldwin Brothers […]

The SG Hiscock fund manager explains why he’s not worried about Ozempic and names the telecom stock he thinks is flying under the radar.

ResMed stock''s high valuation from 4 years ago is finally being reflected in the current stock price. Find out my recommendation on RMD stock.

With the market rallying hard lately, it’s easy to think every stock is participating in the gains. But look a little closer, and you’ll see the rally has been very narrow. Most of these gains have been concentrated heavily in the FAANGs and AI darlings like Tesla (NASDAQ: TSLA ) and Nvidia (NASDAQ: NVDA ) . Many other high-growth companies doing just as well (if not better!) have been left behind. This creates a massive opportunity today for investors willing to venture beyond the crowd favorites. While the market chases the hot momentum stocks, diamonds in the rough are there for the taking. These are stocks worth buying before their share prices catch up to reflect their full value. Here are three growth stocks trading at a massive bargain to snap up right now. Evolution (EVVTY) Source: rawf8/Shutterstock.com Evolution (OTCMKTS: EVVTY ), the Swedish provider of online casino solutions, has seen its stock tumble over 45% from its 2021 peak. However, the company’s business fundamentals remain strong, with Q2 revenue up 28% year-over-year.

ResMed''s 4Q23 sales surge by 23% YoY due to strong device and mask sales. The company''s market potential and future growth remain positive. Learn more on RMD stock here.

Someone with a lot of money to spend has taken a bullish stance on ResMed (NYSE: RMD ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with RMD, it often means somebody knows something is about to happen. Today, Benzinga''s options scanner spotted 11 options trades for ResMed . This isn''t normal. The overall sentiment of these big-money traders is split between 81% bullish and 18%, bearish. Out of all of the options we uncovered, there was 1 put, for a total amount of $31,050, and 10, calls, for a total amount of $428,553.. What''s The … Full story available on Benzinga.com

Needham upgraded ResMed Inc (NYSE: RMD ) from a Hold to Buy rating with a price target of $180 . The analysts Mike Matson , Joseph Conway, and David Saxon note that ResMed''s shares are down 31% since the start of August (versus a 2% decline in the S&P 500), mainly due to concerns about the potential for GLP-1 obesity drugs to reduce demand for ResMed''s sleep therapy devices . The analysts expect two negative effects of GLP-1s. First, patients using continuous positive airway pressure (CPAP) who lose significant weight with … Full story available on Benzinga.com